Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We think that the -- any inventory destocking is behind us and that gives us confidence |
| We believe gross margins will steadily improve throughout the year |
| With stabilization of hospital census and operations post-pandemic our healthy contract backlog and our cutting-edge innovations in growing markets Masimo is well positioned for 2024 |
| In addition to sensor utilization having stabilized, our hospital contract wins have more than doubled from four years ago within our target markets, which has resulted in meaningful gains in market share |
| So, between those things, we feel good about getting up in that mid-60s margin over the next few years |
| So that's going to be a great lever for us as we move forward and really deliver additional growth in earnings as well |
| So for those reasons, our outlook is very positive regardless of the capital |
| In closing, our ability to translate our core technologies and competencies into products that deliver better outcomes for consumers, patients and providers continue to be the engine for long-term growth across all our businesses |
| If you look at the higher end of the range, that assumes more of closer to a 1% census growth, and it also assumes that we see improvement in -- coming from a lot of the installations that we expect throughout the year as we continue to gain new customers and win new customers |
| We are making a positive impact for healthcare across the world and improving Masimo's long-term position |
| And in Delaware, we are making great progress |
| Our team is proud and excited to contribute to these bold efforts |
| Hospital-at-home initiatives continue to gain traction with healthcare systems which see large opportunities to reduce costs and improve outcomes |
| More importantly, our healthcare revenues increased 10% sequentially driven by expected seasonal increases and improved sensor volumes |
| Further our strong hospital conversions in 2023 have resulted in unrecognized contract revenue increasing 4% sequentially and 16% over the prior year to reach $1.5 billion |
| This gives us confidence in our growth outlook for the healthcare business |
| As we've shared in the past, we see great market potential for these applications and have received multiple indications of interest from hospitals |
| However, we made significant progress strengthening our market position which gives us confidence for 2024 and beyond |
| We also had significant new customer wins and a growing contract backlog in healthcare that positions us well for growth this year |
| We are excited about what the Freedom biosensing watch and the H1 hearing-enhancement device will do for consumer health and what our next-generation Root platform will do for healthcare in terms of improving patient care as well as hospital finances |
| We've got a very good path to get to the mid-60s just with things we're doing in Malaysia, with some of the key product cost-reduction efforts that we're undertaking right now and the focus by our engineering and manufacturing teams |
| Our plan to transition a large portion of our sensor manufacturing to Malaysia is well underway and we expect to reap the benefits of increased efficiencies and lower production costs over the next few years |
| We expect to benefit from the improvements in gross margin and disciplined spending partially offset by the return of performance-based compensation to normalized levels |
| And again, we're growing the we're getting into new channels, in new markets with the hearables so that's going to continue to be growth throughout the year that gives us more confidence in that guidance range for non-healthcare |
| There are many reasons to be positive about our prospects this year |
| Over the past-- over the last two quarters, we have gained a better understanding of the shift in customer ordering patterns and have confidence that sensor volumes have stabilized |
| We have a strong contract backlog thanks to a record year for converting new customers and expanding our footprint with existing customers |
| With deeper understanding of post-pandemic market conditions and a strong start to the year for our healthcare business, we are confident in our guidance and look forward to reestablishing our track record of consistency and predictability |
| Besides strong sensor orders, our record customer conversions in 2023, provide the foundation for that confidence and show how our commitment to delivering innovative technologies into the marketplace sustains not only our long-term future but the short-term growth potential |
| We exited 2023 with growing momentum driven by record contract wins for the year in our healthcare business, important FDA clearances for innovative new products and strong growth in our hearables business |
| Statement |
|---|
| Overall, 2023 was a year marked by uneven financial performance as we address shifting environments for both business segments |
| For our non-healthcare segment fourth quarter revenues were $209 million down 23% on a constant currency basis versus prior year |
| Our healthcare revenues were $340 million which was near the upper end of our guidance range and represent a 4% decline on a constant currency basis versus Q4 2022 |
| This business segment increased sequentially due to the holiday season, but declined year-on-year due primarily to challenging macroeconomic conditions including high interest rates which weighed on consumer spending |
| For the non-healthcare segment, we are projecting revenues of $700 million to $780 million representing a 4% decline at the midpoint in constant currency |
| Joe from your public commentary still sounds like there's maybe some difficulties in the Board room to put that maybe gently |
| And it also assumes the weak capital environment that we're seeing |
| But I guess the alternative here is that drivers have fallen for four consecutive quarters |
| So that implies that the range of $700 million to $780 million, at the low end of the range, it would imply high teens decline in the core audio business and the upper end of the range, it would imply a mid-single-digit decline in the upper end of that range |
| I think the lowest absolute figure you've had since the first quarter of 2018 |
| The incentive comp reset is a limiting factor year-on-year |
| Definitely lighter than our model |
| And we think that the replacement cycles of existing equipment have slowed temporarily |
| And then as a follow-up on that the Q1 cadence for consumer maybe a little bit lighter than we were looking for |
| I think they're probably lighter than where most estimates were sitting here |
| Our concern is really getting after new business converting customers to Masimo technologies and placing the equipment in there and return for those recurring sensor revenues that's going to continue to help us grow in the outlook that we've provided for this year |
| So that hearables strength is disguising a bit some of the softness you're expecting in consumer |
| And Joe, you just mentioned maybe kind of a little choppy soft |
| So we think it's going to start heading the right direction based on our internal estimates and that's less of a concern for us |
| Yes I am less concerned about the driver numbers |
Please consider a small donation if you think this website provides you with relevant information